Inventor · disambiguated record
Pamela B. Conley
Also filed as: CONLEY PAMELA · CONLEY PAMELA B
17 granted patents·26 pending applications·117 citations·filing 1995–2025
93Inventor score
Files withALEXION PHARMA INC16PORTOLA PHARM INC15COR THERAPEUTICS INC2MILLENNIUM PHARM INC2SINHA UMA2
Top patents by PatentIndex Score
43 records- 0196US8268783B2Antidotes for factor Xa inhibitors and methods of using the sameSINHA UMA·Filed 2010·Granted Sep 18, 2012·40 cites·25 claims
- 0294US10954503B2Antidotes for factor Xa inhibitors and methods of using the sameALEXION PHARMA INC·Filed 2019·Granted Mar 23, 2021·4 cites·12 claims
- 0394US10954504B2Preparation of factor Xa derivativesALEXION PHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·14 claims
- 0494US9109046B2Antidotes for factor Xa inhibitors and methods of using the sameSINHA UMA·Filed 2012·Granted Aug 18, 2015·21 cites·17 claims
- 0593US9587233B2Antidotes for factor XA inhibitors and methods of using the samePORTOLA PHARM INC·Filed 2015·Granted Mar 7, 2017·10 cites·7 claims
- 0687US11845966B2Preparation of factor Xa derivativesALEXION PHARMA INC·Filed 2021·Granted Dec 19, 2023·1 cites·13 claims
- 0786US10190111B2Antidotes for factor Xa inhibitors and methods of using the samePORTOLA PHARM INC·Filed 2017·Granted Jan 29, 2019·3 cites·10 claims
- 0886US2023383276A1Process for making recombinant antidote to factor xa inhibitorALEXION PHARMA INC·Filed 2023·Application pending·0 cites
- 0983US2024076642A1Preparation of factor xa derivativesALEXION PHARMA INC·Filed 2023·Application pending·0 cites
- 1082US10604748B2Preparation of factor Xa derivativesPORTOLA PHARM INC·Filed 2017·Granted Mar 31, 2020·3 cites·27 claims
- 1179US2025092380A1Antidotes to factor xa inhibitorsALEXION PHARMA INC·Filed 2024·Application pending·0 cites
- 1278US2022098565A1Process for making recombinant antidote to factor xa inhibitorALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 1375US2021340515A1Antidotes for factor xa inhibitors and methods of using the sameALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 1474US6680373B2P2U2 receptor antibodiesMILLENNIUM PHARM INC·Filed 2001·Granted Jan 20, 2004·2 cites·8 claims
- 1571US2019127720A1Process for making recombinant antidote to factor xa inhibitorPORTOLA PHARM INC·Filed 2018·Application pending·0 cites
- 1669US11266645B2Methods for treating lymphomaALEXION PHARMA INC·Filed 2019·Granted Mar 8, 2022·0 cites·15 claims
- 1769US8946219B2Combination therapy with a compound acting as a platelet ADP receptor inhibitorCONLEY PAMELA B·Filed 2010·Granted Feb 3, 2015·2 cites·13 claims
- 1868US12195774B2Antidotes to factor XA inhibitorsALEXION PHARMA INC·Filed 2019·Granted Jan 14, 2025·0 cites·4 claims
- 1968US6989232B2Proteins and nucleic acids encoding sameCURAGEN CORP·Filed 2001·Granted Jan 24, 2006·3 cites·38 claims
- 2067US2021379163A1Inhibition of tissue factor pathway inhibitor with factor xa derivativesALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 2166US2017240879A1Process for making recombinant antidote to factor xa inhibitorPORTOLA PHARM INC·Filed 2016·Application pending·0 cites
- 2266US2022233533A1Methods for treating lymphomaALEXION PHARMA INC·Filed 2022·Application pending·0 cites
- 2365US2013230901A1Process for making recombinant antidote to factor xa inhibitorPORTOLA PHARM INC·Filed 2013·Application pending·0 cites
- 2463US2015352194A1Inhibition of tissue factor pathway inhibitor with factor xa derivativesPORTOLA PHARM INC·Filed 2013·Application pending·0 cites
- 2563US2015376592A1Process for making recombinant antidote to factor xa inhibitorPORTOLA PHARM INC·Filed 2015·Application pending·0 cites
- 2663US2025213562A1Methods for treating lymphomaALEXION PHARMA INC·Filed 2025·Application pending·0 cites
- 2763US2018333469A1Inhibition of tissue factor pathway inhibitor with factor xa derivativesPORTOLA PHARM INC·Filed 2018·Application pending·0 cites
- 2861US6762029B2Methods of identifying agents that modulate P2Y12 receptor activityPORTOLA PHARM INC·Filed 2000·Granted Jul 13, 2004·7 cites·17 claims
- 2961US5871963AP2u2 purinergic receptor and nucleic acid encoding the receptorCOR THERAPEUTICS INC·Filed 1995·Granted Feb 16, 1999·12 cites·26 claims
- 3059US2008241233A1Targeted delivery and expression of procoagulant hemostatic activityPORTOLA PHARM INC·Filed 2008·Application pending·0 cites
- 3158US2023265483A1Methods for testing andexanet potencyALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 3257US2009186810A1Potassium channel modulators and platelet procoagulant activityPORTOLA PHARM INC·Filed 2007·Application pending·0 cites
- 3357US2008279845A1Combination therapy with a compound acting as a platelet adp receptor inhibitorPORTOLA PHARM INC·Filed 2008·Application pending·0 cites
- 3457US2025213559A1Compositions and methods for preventing and treating cytokine release syndromeALEXION PHARMA INC·Filed 2023·Application pending·0 cites
- 3557US2009048216A1Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitorPORTOLA PHARM INC·Filed 2008·Application pending·0 cites
- 3654US2012009172A1Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitorGRETLER DANIEL D·Filed 2011·Application pending·0 cites
- 3751US2004152875A1Novel purinergic receptorMILLENNIUM PHARM INC·Filed 2004·Application pending·0 cites
- 3850US2023181581A1Circulating b cell subpopulations in indolent b cell lymphomaALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 3943US2003165858A1Novel GPCR-like proteins and nucleic acids encoding sameFiled 2001·Application pending·0 cites
- 4043US2003198957A1Proteins and nucleic acids encoding sameFiled 2002·Application pending·0 cites
- 4142US2002082206A1Novel polynucleotides from atherogenic cells and polypeptides encoded therebyFiled 2001·Application pending·0 cites
- 4238US6063582AMethods of screening for compounds that interact with human P2u2 purinergic receptorCOR THERAPEUTICS INC·Filed 1996·Granted May 16, 2000·5 cites·12 claims
- 4330US6667306B1Platelet ADP receptor inhibitorsPORTOLA PHARM INC·Filed 1999·Granted Dec 23, 2003·0 cites·15 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →